Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
Industry Spotlights & Insight Articles

Discussion Group Announcement

Edited by Tia Byer | 27 July 2022
Oxford Global’s next round of Biologics Discussion Groups announced.

Our monthly Discussion Groups are hosted by a panel of leading industry experts who explore some of the key issues facing biologics research and development today. The interactive sessions provide a focused networking opportunity for a handful of like-minded experts in an online format.

Bringing together an exclusive panel of key opinion leaders for an hour of specialist discussion, each session addresses the critical growth factors, challenges, and future opportunities for the expansive biologics field and market.

For the next round of Discussion Groups, we will be exploring cutting-edge vaccine technologies and applications, as well as developing the next generation of biotherapeutics. With an array of hand-picked panel experts lined-up to lead stimulating and thought-provoking debates, these exclusive sessions are not-to-be-missed!

-

1.) Advanced Vaccine Platforms & Technologies

Taking place Friday 9th September 2022 | 15:00 BST (09:00 EST)

Discussion Topics:

  • Vaccine platform technologies
  • Development of modern vaccine technologies (mRNA, viral vectors, DNA and rapid response platforms)
  • Industry opportunities and challenges

Discussion Leaders:

  • Wieslaw Swietnicki, Head Of Research And Development at ?ukasiewicz Research Network – Institute of Industrial Organic Chemistry
  • Slobodanka Dina Manceva, Senior Scientist at Teva Pharma

Oxford Global's Discussion Groups

2.) Exploring & Developing Various Biotherapeutics Modalities

Taking place Tuesday 18 October 2022 | 15:00 BST (09:00 EST)

Discussion Topics:

  • Accelerating the development of next-generation therapeutics
  • Overcoming challenges in analytical method development

Discussion Leaders:

  • Peter D. Westenskow, Senior Principal Scientist and Section Head at Roche Pharma Research & Early Development
  • Slobodanka Dina Manceva, Associate Director at Teva Pharma
  • Smita Raghava, Associate Principal Scientist at Merck
  • Jonathan Davis, Vice President of Innovation and Strategy at Invenra

-ion Groups

3.) Universal Vaccines & Vaccine Therapeutics

Taking place Thursday 3 November 2022 | 15:00 GMT (11:00 EDT)

Discussion Topics:

  • Existing and Approved Immunotherapies
  • Broadening the Horizons for Immunotherapy
  • Understanding Mechanisms of Action

Discussion Leaders:

  • Mark Doherty, Senior Medical Manager at GSK
  • Slobodanka Dina Manceva, Senior Scientist at Teva Pharma

-

Attendance to our Discussion Groups is available to members of our Biologics Member Community. For more information about Membership, please click here.

Join Oxford Global‘s 2023 Biologics UK: In-Person event today. Happening in March, this 3-day conference brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and exciting industry outlooks.

Get your bi-weekly dose of industry news here and keep up to date with the latest 'Industry Spotlight' posts. For other Biologics content, please visit the Biologics Content Portal.

Related Resources

GSK Buys CureVac's mRNA Vaccine Business Providing Welcome Cash Injection

CureVac will continue to build its R&D pipeline while allowing GSK to develop and commercialise a handful of its prophylactic mRNA vaccines.
Read More

H5N1 Bird Flu Outbreaks: Effect on Vaccines

H5N1 outbreaks in the US have mobilised pandemic preparedness mechanisms with stockpiling of avian flu vaccines.
Read More